Last reviewed · How we verify
NCT06585046
Pancreatic Surgery and Risk Factors
trial testing pancreatic surgery in Pancreatic Surgey in 382 participants. Completed in 1 August 2024.
1 August 2024
Quick facts
| Lead sponsor | Shanghai Changzheng Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 382 |
| Start date | 1 January 2017 |
| Primary completion | 1 August 2024 |
| Estimated completion | 1 August 2024 |
Drugs / interventions tested
- pancreatic surgery
Conditions studied
- Pancreatic Surgey — all drugs for Pancreatic Surgey →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
Sponsor
Shanghai Changzheng Hospital
Who can join
Adults 18 to 80, any sex, with Pancreatic Surgey or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about post-pancreatic surgery diabetes mellitus(PCRD).The main questions it aims to answer are: 1. What are the clinical characteristics of PCRD? 2. What are the related factors for PCRD? All patients with pancreatic surgery have been given standardized treatment fot the condition. The researchers will summarize the risk factors for PCRD from the PCRD group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06585046
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of pancreatic surgery
Trials testing the same drug.
- NCT05711433 — Risk Factors for Postoperative Pancreatic Fistula Following Non-traumatic Pancreatic Surgery. Retrospective Observationa · completed
Other Shanghai Changzheng Hospital trials
Trials by the same sponsor.
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06585046 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585046.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing